Turn TherapeuticsTTRX
13F holders, Q4 2025 (December 31)22holders
2famous investors
$3.94avg. 13F price*
At the end of Q4 2025, 22 institutions reported holding Turn Therapeutics Inc. (TTRX) in their 13F filings. The largest holders were Millennium Management ($377K), Wellington Shields & Co., LLC ($259K) and DDFG, Inc ($206K). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Turn Therapeutics Inc.
- CUSIP
- 90021W105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 22 | $1.8M |
| Exits | 0 | $0 |
Ownership 22 holders
| Millennium Management | 0.00% | New | 95,623 | $377K |
| Wellington Shields & Co., LLC | 0.06% | New | 65,732 | $259K |
| DDFG, Inc | 0.05% | New | 52,288 | $206K |
| Vanguard Group Inc. | 0.00% | New | 30,156 | $119K |
| XTX Topco Ltd | 0.00% | New | 25,173 | $99K |
| Brown Brothers Harriman & Co. | 0.00% | New | 23,688 | $93K |
| Citadel Advisors | 0.00% | New | 20,986 | $83K |
| HighTower Advisors, LLC | 0.00% | New | 19,684 | $78K |
| RVW Wealth, LLC | 0.01% | New | 18,000 | $71K |
| Jane Street Group, LLC | 0.00% | New | 17,169 | $68K |
| Geode Capital Management, LLC | 0.00% | New | 17,142 | $68K |
| Composition Wealth, LLC | 0.00% | New | 16,000 | $63K |
| Tamar Securities, LLC | 0.01% | New | 15,000 | $59K |
| Bank of America Corp. | 0.00% | New | 14,124 | $56K |
| LPL Financial LLC | 0.00% | New | 13,000 | $51K |
| Hodges Capital Management Inc. | 0.00% | New | 10,000 | $39K |
| Morgan Stanley | 0.00% | New | 10,000 | $39K |
| Blue Trust, Inc. | 0.00% | New | 1,122 | $4K |
| Wells Fargo & Company | 0.00% | New | 1,000 | $4K |
| Royal Bank of Canada | 0.00% | New | 267 | $1K |
| Pflug Koory, LLC | 0.00% | New | 170 | $670 |
| Tower Research Capital LLC (TRC) | 0.00% | New | 137 | $540 |
"% of holder's portfolio" is TTRX's weight in each manager's 13F, not the share of Turn Therapeutics Inc. the manager owns.